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Abstract
Purpose The aim of this study is to investigate the
mechanisms of interactions between TGF-b and Wnt/b-
catenin pathways that induce and regulate EMT and pro-
mote breast cancer cells to become resistant to treatment.
Methods The effect of TGF-b on Wnt/b-catenin signaling
pathway was examined by using a human Wnt/b-catenin-
regulated cDNA plate array and western blot analysis. The
interaction of Twist at promoter of Wnt3 was examined by
chromatin immunoprecipitation (ChIP) assay. Secreted
Wnt3 level was determined by ELISA assay.
Results HER2-overexpressing breast cancer cells treated
with TGF-b have a reduced response to trastuzumab and
exhibited EMT-like phenotype. The TGF-b-induced EMT
in HER2-cells was concordant with upregulation of Wnt3
and b-catenin pathways. The TGF-b-induced induction of
Wnt3 during EMT was found to be Smad3-dependent.
ChIP analysis identified occupancy of Twist at promoter
region of Wnt3. Knock-down of Twist by shRNA con-
firmed the significance of Twist in response to TGF-b
regulating Wnt3 during EMT. Subsequently, TGF-b-in-
duced matrix metalloproteinases, MMP1, MMP7, MMP9,
MMP26, Vascular endothelial growth factors (VEGF), and
activation of Wnt/b-catenin signaling were repressed by
the shRNA treatment. TGF-bR1 ALK5 kinase inhibitor,
A83-01 can effectively prevent the TGF-b-induced Twist
and Wnt3. Co-treating A83-01 and trastuzumab inhibited
TGF-b-induced cell invasion significantly in both trastu-
zumab responsive and resistant cells.
Conclusions Our data demonstrated an important interde-
pendence between TGF-b and Wnt/b-catenin pathways
inducing EMT in HER2-overexpressing breast cancer cells.
Twist served as a linkage between the two pathways during
TGF-b-induced EMT. A83-01 could inhibit the TGF-b-
initiated pathway interactions and enhance HER2-cells
response to trastuzumab treatment.
Keywords TGF-b  Smad3  Wnt3  Twist  EMT
Introduction
TGF-b could act as a tumor suppressor by inhibiting cell
proliferation in early carcinogenesis, however, at late stage,
TGF-b pathway could interact with other oncogenic path-
ways and promote cancer progression [1–6]. As a tumor
promoter, TGF-b has been shown to induce core tran-
scription factors, Snail, Slug, and Twist, and promote EMT
and cell invasiveness in different cell types [7–9].
The signal transduction by TGF-b is through its two
transmembrane serine/threonine kinase receptors, type II
receptor (TGFbRII) and type I receptor (TGFbRI). The
TGFbRII activates TGFbRI, which leads to activation of
the cellular response to TGF-b [1, 10]. TGF-b-induced
EMT could be mediated through both Smad-dependent and
Smad-independent pathways [11]. In Smad-dependent
pathways, TGF-b induces activation of the receptor
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complex and activates Smad2 and Smad3. The phospho-
rylated Smad2 and Smad3 recruit Smad4, and translocate it
into the cell nucleus, where they associate and/or cooperate
with DNA-binding transcription factors to influence the
targeted gene transcription [11, 12].
Wnt/b-catenin signaling pathway also plays a critical role
in EMT and cell invasion in cancer cells including breast
cancer cells [13–15]. The Wnt signaling pathway can be
initiated by bindingWnt ligands to transmembrane receptors
of the Frizzled family. This leads to the destruction of APC
complex, cell–cell adhesion, and E-cadherin. As a result, b-
catenin accumulates in the nucleus, forming the b-catenin/
TCF/LEF transcriptional complex, and drives transactiva-
tion of the Wnt signaling-targeted genes which promote
EMT and cell invasion [16, 17]. We recently demonstrated
that in trastuzumab-resistant HER2-overexpressing breast
cancer cells, Wnt3 was significantly upregulated [18]. The
upregulation of Wnt3 activates b-catenin pathway that leads
to the transactivation of EGFR and promotes EMT-like
transition. Considering that tumor microenvironments are
often enriched in secreted TGF-b [19], hence it is possible
that TGF-b signaling pathway could provide a favorable
environment for the dysregulation of the Wnt3/b-catenin
pathway in the HER2 cells. There may be pathway interac-
tions or network sustaining that leads to EMT and then
activation of EGFR pathway, eventually leading to resis-
tance. In this study we further investigated the interactions
between TGF-b and Wnt/b-catenin pathways in the regula-
tion of EMT and promoting breast cancer cells’ invasion.
Data from our study demonstrated that TGF-b-induced EMT
in HER2 cells was coordinated with the activation of Wnt3/
b-catenin pathways. In response to TGF-b, Twist was able to
regulate Wnt3 during EMT and then activated b-catenin
pathway. Targeting TGFbR1 ALK5 kinase by A83-01 pre-
vented TGF-b-induced induction of Twist and Wnt3, and
enhanced the anti-tumor activity of trastuzumab. The data
suggested modulation of TGF-b/Smad pathway by small
molecule inhibitors, such as A83-01, may provide a novel
approach to therapeutic intervention of TGF-b-initiated
pathway interaction and EMT in breast cancer, especially in
HER2-overexpressing breast cancer. Furthermore, thera-
peutic targeting of Twist could inhibit TGF-b-induced
upregulation of Wnt3 and enhance the sensitivity of chemo
and target therapies, and subsequently could prevent tumor
metastases caused by TGF-b.
Methods
Cell lines and culture
The human breast cancer cell lines SKBR3 (HTB-30) and
BT474 (HTB-20) were obtained from American Type
Culture Collection. Monolayer cultures of the cells were
maintained in DMEM/F12 medium with 10% fetal bovine
serum. The cell lines overexpressed the HER2/c-erb-2
(HER2) gene product. The JIMT-1 cell line that was
established from a breast cancer patient who clinically
demonstrated resistance to trastuzumab was purchased
from German Collection of Microorganisms and Cell
Cultures. The JIMT-1 cell line also showed HER2 over-
expression [20]. Both SKBR3 and JIMT-1 lacked expres-
sions of estrogen and progesterone receptors (ER/PR) and
BT474 expresses ER in addition to HER2 receptor.
Treatment with TGF-b, Wnt3, or inhibitors
The cells were serum starved overnight and then incubated
with serum-free medium containing 5% Bovine serum albu-
min (Sigma) and 10 ng/ml of human TGF-b1 (100-B-001,
R&D) at different time points. The A83-01
(SML0788 Sigma) was used at 1 lM and prior to TGF-b
treatment for 2–16 h. The trastuzumab for this study was
donated by Genentech. Human recombinant Wnt3 protein
was purchased from Abnova and 50 ng/mL of Wnt3 protein
was used to induce Smad pathway. TheLGK974 (s7143),was
obtained fromSelleck,USAand 1 nMwasused for treatment.
Human Wnt/b-catenin-regulated cDNA plate array
The Wnt/b-catenin-regulated cDNA plate array (AP-0171)
was purchased from Signosis Sunnyvale, CA and consisted
of 22 Wnt/b-catenin pathway-regulated genes [18]. After
treatment with TGF-b for 4 days, total RNA was isolated
from cells utilizing RNeasy micro kit (#74004, QIAGEN).
The quality of RNA was determined by separation of the
RNA via capillary electrophoresis using the Agilent 2100
Bioanalyzer. cDNA was synthesized and plate array was
created as per manufacturer’s instructions.
Measurement of Wnt3 in conditioned medium
utilizing ELISA test
The cells were treated with TGF-b, TGF-b ? anti-TGF-b
antibody, TGF-b ? anti-Wnt3 antibody, or antibodies alone
for 24 h and then collected the medium to measure Wnt3 by
ELISA using Human wingless-type MMTV integration site
family, member 3 ELISA Kit (MyBioSource #MBS919345).
The attached cellswere collected and counted.TheWnt3 level
was calculated and normalized as ng/ml, per 1million cells/ml
according to manufacturer’s instructions.
Knock down of Twist1 gene
shRNA construct for human Twist1 (TF308556) was pur-
chased from OriGene, Rockville, MD. One set of shRNA
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constructs contains four Twist1-specific shRNA sequences
(A, B, C, D) expressed in pRFP-C-RS vector. Lipofec-
tamineTM 2000 transfection reagent (11668-019, Invitrogen)
was used for transfection following the manufacturer’s
instructions, and Puromycin (20 mg/ml) was used for clonal
selection. The negative sequence for Twist1 (purchased from
the same company) was also transfected in the cell lines.
Scratch wound healing assay
The cells were seeded in a 6-well plate until the adherent
monolayer reached 70–80% confluence and the scratches
were created. After washing with PBS some of the cells
were placed in fresh medium containing trastuzumab and/
or A83-01 and others were place in fresh medium without
Trastuzumab and/or A83-01. Each condition was dupli-
cated. The images were taken after 48 h and three mea-
surements of wound width were made at random points.
Boyden chamber invasion assay
The invasive assay was done in 24-well cell culture cham-
bers using inserts with 8 lm pore membranes pre-coated
with Matrigel (Sigma). Cell suspensions were placed in the
upper wells without serum and medium containing serum or
MDA-MB231 cellswere filled in the lowerwells. After 24 h,
the cells were fixed by 0.5% glutaraldehyde and stained with
0.5% toluidine blue. The numbers of invaded cells were
counted utilizing 209 objective microscope from three files
per membrane and then normalized with total number of
cells. Each experiment was performed twice and each con-
ditioning was duplicated.
Chromatin immunoprecipitation real-time PCR
assay (ChIP-qPCR)
The cells were treated with or without TGF-b for 48 h. The
chromatin protein complex from the cells was prepared by
immunoprecipitation of the chromatin with Twist1 anti-
body (ab50887, abcam) using Magna ChIP assay kit (17-
10085, Millipore) following the manufacture’s instruction
and then qPCR with Wnt3 promoter primers was per-
formed. The primer sequences were designed to cover the
Twist1-binding region of the promoter of Wnt3 (640–660):
Lt: 50-AAGGAGCCACCCGTTCAT-30 and Rt: 50-CCAG-
CAAACTTGGGCAAA-30. Fold enrichment in the Twist1-
precipitated samples was calculated relative to the mock
samples (precipitated with normal IgG).
Immunoblotting analysis
The NE-PER nuclear and cytoplasmic extraction reagents
(78833, Thermo-Scientific) were used to extract the nuclear
and cytoplasmic protein following the manufacturer’s
instructions. The antibodies used for Immunoblotting were
b-catenin (cell signaling); TGF-bRI, TGF-bRII, phospho-
Smad3 at ser423/425 and E-cadherin (Santa Cruz Biotech-
nology); Twist1 and Wnt3 (abcam). b-actin (sigma), a-
Tubulin (Santa Cruz Biotechnology), and Histone 3 (H3)
(cell signaling) were used for loading control or for confir-
mation of cytoplasmic and nuclear protein extraction.
Immunofluorescence (IF)
IF was carried out using antibodies for phospho-Smad3,
Twist, and b-catenin according to manufacturer’s recom-
mended dilutions and incubated overnight followed by
incubation with fluorescence-conjugated secondary anti-
bodies for 30 min and then mounted with Vectashield,
mounting medium. Cell nuclei were counterstained using
40,6-diamidino-2-phenylindole (DAPI) (D9542; Sigma-
Aldrich). Image was taken with a microscopy digital
camera (Olympus BioScapes) under the light microscope
reviewed by pathologist.
Statistical analyses
Data were analyzed using one-way Anova or the t test with
SPSS 13.0 software. p\ 0.05 indicates a statistically sig-
nificant difference.
Results
TGF-b induces mesenchymal phenotype in HER2
cells and concordantly upregulates Wnt3 and b-
catenin pathway signaling
We first treated HER2-overexpressing breast cancer cells
with TGF-b over several days. Morphologic changes in
SKBR3 cells were observed after two days of TGF-b
treatment, as shown in Fig. 1a(left), the cells started losing
cell–cell contact and displayed spindle shape. However, the
cell growth was inhibited during the first three days of
TGF-b-treatment and then the cell growth increased again
after 4 days of treatment (Fig. 1a(right)). Cadherin switch,
decreasing E-cadherin and increasing N-cadherin, and
upregulation of zinc finger transcription factors, Snail,
Slug, and Twist (Twist1), were detected after 24 h treat-
ment with TGF-b (Fig. 1b). For the same period of time the
cell invasiveness was found to have been increased by 35%
(Fig. 1c). Data in Fig. 1d show the changes in the protein
levels of Twist, N-cadherin, and E-cadherin by TGF-b. As
shown in Fig. 1d the protein levels of Matrix Metallopro-
teinase-7 (MMP7) were also increased upon TGF-b
induction.
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Previously we have identified that upregulation of Wnt3
promoting EMT in HER2-overexpressing breast cancer
cells is an important mechanism leading to trastuzumab
resistance [18]. The Wnt3 expression was increased more
than 3-fold in JIMT-1 and more than 2-fold in SKBR3/100-
8 (a Trastuzumab-resistant cell line generated from SKBR3
[18]) compared to SKBR3 and BT474 (Supplement-
Fig. 1A). The secreted Wnt3 in conditioned medium from
JIMT1 cells was also higher than that in the conditioned
medium from SKBR3 cells, and the upregulated mRNA
levels of Wnt3 and Twist in JIMT1 were confirmed again
(Supplement-Fig. 1B). The protein levels of TGF-bRs
(TGF-bRII and TGF-bRI) and phosphorylated Smad3 were
also higher in Trastuzumab-resistant cell, JIMT1, com-
pared with the sensitive cells, SKBR3 and BT474 (Sup-
plement-Fig. 1C). The data suggested that TGF-b and
Wnt3 pathways are constitutively upregulated in the
Trastuzumab-resistant cells. Hence, it is important to
understand that if the two pathways sustain each other to
affect HER2 cell response to treatment.
Next, we examined the effect of TGF-b on Wnt/b-
catenin signaling pathway using a human Wnt/b-catenin-
regulated cDNA plate array. The data showed that 64% of
the genes in the array were upregulated more than 2 fold
upon TGF-b induction. Among those upregulated genes,
c-Jun, c-Myc, NOS2, PPARd were upregulated by 5 fold,
while Nanog and Vascular endothelial growth factor
(VEGF) were upregulated approximately by 16 fold
(Fig. 2a). Furthermore, all four matrix metalloproteinases,
MMP1, MMP7, MMP9, and MMP26 were significantly
upregulated. To determine if the TGF-b-induced activation
of Wnt/b-catenin pathway signaling is ligand dependent,
Fig. 1 TGF-b induces EMT phenotype enhances cell invasion of
HER2-overexpressing breast cancer cells. a SKBR3 cells were treated
with TGF-b for 4 days and changes in cell morphology were observed
at the indicated days (left panel). The bar graph in right is quantified
data of the left panel. The bars indicated mean number of total cells
plus standard deviation counted from five different areas, *p\ 0.05
compared to untreated cells. b SKBR3 and BT474 cells were treated
with or without TGF-b for 24 h and RT-PCR was performed with the
indicated genes’ primers. The bars indicate relative expression of the
indicated genes (mean ± SD from three determinations) adjusted
with 18S, *p\ 0.05 compared to untreated cells. c SKBR3 cells were
treated with or without TGF-b for 24 h and cell invasiveness was
measured by Boyden Chamber Invasion assay as described in
‘‘Methods’’ section. The invasive cells (mean ? SD from five
different areas) were counted, *p\ 0.05 compared to untreated cells.
d SKBR3 cells were treated with or without TGF-b and the indicated
protein expressions were analyzed by Western blot analysis. The b-
actin was used as loading control
452 Breast Cancer Res Treat (2017) 163:449–460
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especially if it is Wnt3 dependent, we examined several
Wnt ligands and Fizzed receptors upon TGF-b induction.
Among the different Wnt ligands TGF-b significantly
upregulated Wnt3 and slightly upregulated FZD1 and
FZD5 in SKBR3 cells (Fig. 2b). The baseline level of
Wnt3 in conditioned medium from JIMT1 cells was higher
than that in conditioned medium from SKBR3 cells and the
secretion of Wnt3 was further increased significantly fol-
lowed by TGF-b induction in both SKBR3 and JIMT1 cells
(Fig. 2c(left)). The TGF-b-induced Wnt3 secretion was
repressed by co-treating the cells with TGF-b and TGF-b
antibody or TGF-b with Wnt3 antibody (Fig. 2c(left)). The
immunodepletion of Wnt3 not only repressed Wnt3
secretion and expression, but also downregulated mRNA
Fig. 2 TGF-b upregulates Wnt3 and activates b-catenin pathway.
a Bar graph of regulated Wnt/b-catenin pathway signaling in SKBR3
treated with TGF-b (dark bars) compared to untreated SKBR3 (open
bars) analyzed by specific Wnt/b-catenin mRNA array as described in
‘‘Methods’’ section. The relative level of each indicated gene was
adjusted with GAPDH and each bar indicates mean fold change and
SD from four determinations, *p\ 0.05 and **p\ 0.01 compared to
untreated cells. b SKBR3 cells were treated with TGF-b for 24 h and
RNA was extracted. RT-qPCR was performed with the primers for
Wnt ligands (left) and FZD receptors (right). The bars indicate
relative expression of the indicated genes adjusted to 18S
(mean ± SD from three determinations), ^p\ 0.05 compared to the
untreated SKBR3 cells, *p\ 0.05 compared to untreated cells. c The
cells were treated with TGF-b ± anti-TGF-b antibody for 24 h or
TGF-b ± anti-Wnt3 antibody. The medium was collected and the
attached cells were used for extraction of RNA or protein. c (left) The
Wnt3 level in the conditioned medium was measured by ELISA and
calculated as per one million cells/ml as described in ‘‘Methods’’
section. The bars indicate mean from two experiments (each
experiment had duplicated measurements) plus standard deviation,
*p\ 0.05 compared to untreated cells, ^p\ 0.05 compared to
untreated SKBR3 cells (control). c (middle) RT-qPCR was performed
with Wnt3 and Twist primers. The bars indicate relative expression of
Wnt3 or Twist (mean ± SD from three determinations) and adjusted
for 18S. The dark and open bars indicate RNA from the cells without
or with incubation with Wnt3 antibody respectively. The fold changes
were compared to cells without incubation with Wnt3-antibody.
c (right) Western blot was performed with antibody specific against
Twist and b-actin was used for loading control. d (left), SKBR3 was
pre-treated with LGK974 for 16 h and then treated with TGF-b for
additional 24 h. Cell invasiveness was measured by Boyden Chamber
Invasion assay as described in ‘‘Methods’’ section. The invasive cells
(mean ± SD from five different areas) were counted. *p\ 0.05
compared to untreated cells. d (right) The nuclear or cytoplasm
expressions of b-catenin were determined by Western blot analysis
upon treatment with TGF-b ± LGK974. The a-Tubulin and H3 were
used for loading control of cytoplasm and nuclear protein respectively
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and protein level of Twist in both SKBR3 and JIMT1 cells
(Fig. 2c(middle and right)). LGK974 is an inhibitor of
PORCN and blocks secretion of Wnts. Pre-treated SKBR3
cells with LGK974 repressed TGF-b-induced cell invasion
(Fig. 2d(left)). The TGF-b-induced nuclear accumulation
of b-catenin was also blocked by LGK794 (Fig. 2d(right)).
Those data further confirmed that the TGF-b-induced cell
invasion is Wnt dependent.
TGF-b-induced EMT and Wnt3 are Smad3
dependent
Next, we examined the role of Smad pathway in TGF-b-
induced EMT and upregulation of Wnt3 in HER2-over-
expressing cells. SKBR3 cells were treated with TGF-b
from 15 min to 24 h, and the phosphorylation of TGF-b
receptors was examined. As shown in Fig. 3a, the
phosphorylation of TGFbRII was observed at 15 min,
peaked at 30 min, and then decreased after 30 min of
induction, while the phosphorylation of TGFbRI remained
for 1 h. The phosphorylation of Smad2/3 (pSmad2/3) was
also increased by TGF-b, however, the pSmad3 (lower
band) increase was more conspicuous (Supplement-Fig. 2).
The increased pSmad2/3 was completely blocked by the
A83-01 (Supplement-Fig. 2). Then we examined the effect
of TGF-b in the upregulation of pSmad3. The TGF-b-in-
duced pSmad3 protein at serine 423/425 was observed at
1 h and remained up to 24 h (Fig. 3a). While the protein
level of Twist was upregulated upon 4 h of TGF-b
induction and the E-cadherin was downregulated at the
same time (Fig. 3a). Figure 3a also shows that Wnt3 pro-
tein was upregulated after TGF-b induction for 6 h and
significantly increased after TGF-b treatment for 24 h.
Similar observation was made with JIMT1 and BT474
Fig. 3 TGF-b-induced EMT and Wnt3 are Smad3 dependent.
a SKBR3 cells were treated with TGF-b for 15 min to 24 h. Total
protein was extracted at the indicated time points. To measure the
phosphorylated TGF-bRI and TGF-bRII, immunoprecipitation was
performed by incubating protein lysis with phosphor-Tyrosine
antibody first followed by Western blot analysis with antibodies
specific to TGFbRI and TGFbRII. The phospho-Smad3 (pSmad3),
Twist, E-cadherin, and Wnt3 protein levels were also determined by
Western blot analysis. The b-actin was used as loading control.
b BT474 and JIMT1 cells were treated with TGF-b from 1 to 24 h
and Western blot analysis was performed with the indicated
antibodies. c Cells were treated with siSmad3 or negative sequence
(Mock) for 48 h. TGF-b was added into the media containing
siSmad3 or negative sequence after 24 h siSmad3 treatment. RT-
qPCR was performed with Twist (left) and Wnt3 (right) primers. The
bars indicate relative expression of the indicated genes adjusted to
18S (mean ± SD from three determinations), *p\ 0.01 compared to
untreated cells. d In the left panel, BT474 cells were treated with
recombinant human Wnt3 protein at the indicated time and total
protein was extracted. The pSmad3 was determined by Western blot
analysis. The b-actin was used as loading control. In right panel,
SKBR3 cells was treated with or without recombinant human Wnt3
protein for 24 h and then cytoplasmic and nuclear fragment was
extracted. The pSmad2/3 was determined by Western blot analysis.
The a-Tubulin and H3 were used for loading control of cytoplasm and
nuclear protein respectively
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(Fig. 3b). Knock down of Smad3 by siRNA inhibited TGF-
b-induced upregulation of Twist and Wnt3 in both SKBR3
and JIMT1 cells, suggesting the Smad3-dependent regula-
tion of Twist and Wnt3 by TGF-b in HER2 cells (Fig. 3c).
Next we questioned if the TGF-b-mediated Wnt signaling
could interact with the Smad pathway. We exogenously
treated SKBR3 and BT474 cells with recombinant human
Wnt3 protein for 24 h. The data showed that pSmad3
protein was significantly upregulated in BT474 cells which
were treated with Wnt3 for 2 h and the upregulated
pSmad3 was sustained after 24 h (Fig. 3d(left)). The
Fig. 3d(right) demonstrates that Wnt3 was able to induce
nuclear accumulation of both pSmad2 and pSmad3 in
SKBR3 cells after 24 h treatment. The data suggested that
there is a feedback loop between TGF-b and Wnt/b-catenin
pathways inducing EMT in HER2-overexpressing breast
cancer cells.
Twist binding to E-box at the Wnt3 promoter
to regulate Wnt3 during TGF-b-induced EMT
Twist, a basic helix-loop-helix (bHLH) transcription factor, is
characterized by a basic DNA-binding domain that targets the
consensus E-box sequence 50-CANNTG-30 [21]. Using
Matinspector on the Genomatix server (www.genomatix.de)
[22], an E-box sequence at the promoter ofWnt3 gene located
at-640 to-660 relative to the transcription start site?1 was
identified. Following TGF-b treatment, chromatin immuno-
precipitation confirmed the Twist binding to E-box at the
Wnt3 promoter to regulate Wnt3 during the TGF-b-induced
EMT. Data in Fig. 4a showed that the occupancy of Wnt3
promoter region by Twist was approximately 5-fold enriched
in SKBR3 cells and 4-fold enriched in JIMT1 cells compared
with IgG control. TGF-b further increased the occupancy of
Twist atWnt3 promoter regionby2-fold in SKBR3 and 4-fold
in JIMT1 compared with the cells without treating with TGF-
b, respectively. Knock down of Twist by shRNA decreased
Wnt3 protein expression (Fig. 4b(right)).Western blot data in
Fig. 4c showed that nuclear accumulation of b-catenin by
TGF-b was also inhibited by the shRNA knocking down
Twist. Subsequently, TGF-b-induced MMPs, VEGF, and
activation of Wnt/b-catenin signaling were repressed by the
shRNA treatment (Fig. 4d). These findings indicate the criti-
cal role of Twist in the interactions between the TGF-b and
Wnt/b-catenin pathways.
Inhibition of Smad3-dependent TGF-b pathway
by A83-01 prevented TGF-b-induced Twist
and Wnt3, enhanced HER2 cells’ response
to trastuzumab treatment
The A83-01, has been shown to inhibit TGFbRI ALK5
kinase activity, prevent phosphorylation of Smad2, and
subsequently inhibit TGF-b-induced EMT [23]. In our
study A83-01 inhibited TGF-b-induced pSmad3 at serine
423/425 and prevented nuclear accumulation of pSmad3.
As shown in Fig. 5A, SKBR3 cells pre-treated with A83-
01 inhibited TGF-b-induced pSmad3 and Twist. The
nuclear translocation of pSmad3 by TGF-b was inhibited
(Fig. 5B(a–f)) and Twist expression in cell nucleus was
also repressed (Fig. 5B(g–l)). TGF-b-induced nuclear
expression of b-catenin was also inhibited by A83-01
(Fig. 5C). Besides, A83-01 prevented the TGF-b-induced
upregulation of Wnt3 protein (Fig. 5D).
Furthermore, targeting TGFbRI-ALK5 kinase by A83-
01 resulted in reducing TGF-b-induced cell invasion/mi-
gration and enhancing HER2 cells’ sensitivity to trastuzu-
mab treatment. Data from this study showed that TGF-b
reduced the growth rate in the first 3 days, and then the cell
growth rate was increased after 4 days (Fig. 6a). Consistent
with the previous report [23], A83-01 blocked the growth-
inhibitory effect of TGF-b (Fig. 6a). However, the cell
invasion was significantly increased after 24 h of TGF-b
treatment (Fig. 6b). The TGF-b-induced cell invasion was
inhibited 24% by trastuzumab, and 35% by A83-01,
respectively, compared to the cells treated with TGF-b
alone. The trastuzumab in combination with A83-01 was
able to completely block the TGF-b-induced cell invasion
(Fig. 6b). The TGF-b-induced cell migration in JIMT1
cells was also reduced greatly by the combination treat-
ment (Fig. 6c). The Fig. 6c(top) demonstrated the migra-
tion of JIMT1 cells upon different treatment and
Fig. 6c(bottom) showed the quantified migrating level
(wound width compared to Control cells) of JIMT1 cells at
each treatment. As shown in Fig. 6c(bottom) that A83-01
alone reduced approximately 17% cell migration of JIMT1
and trastuzumab alone inhibited 20% cell migration, while
in combination of A83-01 and trastuzumab synergistically
inhibited JIMT1 cell migration up to 90%. The inhibitory
effects of A83-01 suggest the therapeutic potential of
inhibiting ALK5 kinase for treating TGF-b-induced HER2-
positive tumor.
Discussion
TGF-b-induced EMT plays an important role in cancer cell
resistance to chemotherapy and progression to metastases
[24–26]. Wnt/b-catenin signaling pathway is also impli-
cated in playing a critical role in EMT and appears to be
associated with resistance to therapeutic treatment in
aggressive types of cancer [16, 17, 27–29]. Data from our
previous study suggested that activation of Wnt3/b-catenin
signaling pathway in HER2-overexpressing breast cancer
cells leads to transactivation of EGFR and trastuzumab
resistance [18]. Although both TGF-b and Wnt/b-catenin
Breast Cancer Res Treat (2017) 163:449–460 455
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signaling pathways play a dominant role in the initiation of
EMT, the two pathways often cooperate in regulating gene
expression and the EMT process [30]. In our current study
we continually investigated the mechanism of TGF-b and
Wnt pathways cooperatively regulating EMT.
Our data demonstrated that TGF-b-induced EMT in
HER2 cells was coordinated with the upregulation of Wnt/
b-catenin pathway. There was a Smad3-dependent feed-
back loop between TGF-b and Wnt/b-catenin pathways
inducing EMT in the HER2 cells. The TGF-b-induced
Wnt3 acts as a secreted factor and further drives not only b-
catenin signaling, but also Smad pathway. The small
molecular inhibitor, LGK974 is a potent and specific
PORCN inhibitor, and has been tested blocking Wnt1, -2, -
3, -3A, -6, -7A, and -9As [31]. It has also been shown to
have strong efficacy in animal tumor models, and to be
well tolerated [31]. In this study TGF-b-induced cell
invasion was repressed by LGK974, suggesting that the
Wnt-dependent invasion was induced by TGF-b. The
siRNA knocking down Smad3 confirmed Smad3-depen-
dent interaction between TGF-b and canonical Wnt path-
way. Smads, especially Smad2 and Smad3, have been
recognized as important intracellular mediators of TGF-b
signaling and controlling transcriptional effects of TGF-b
signaling during EMT [11, 32]. The nuclear localization of
Smad3 was shown to enhance Twist, leading to EMT by
repressing ID2 interaction with transcription factor 3
(ATF3) in epithelial cells from different organs including
mammary epithelial cells, MCF-10A [33]. Our data in this
study showed that nuclear accumulation of Smad3 by TGF-
Fig. 4 TGF-b induces Twist transcriptionally upregulating Wnt3 and
leads to activate Wnt/b-catenin pathway. a top E-box located in
promoter of Wnt3 where Twist binding allowed; bottom Cells were
treated with or without TGF-b and ChiP-qPCR assay was performed
as described in ‘‘Methods’’ section. The bars indicate the fold
enrichment of Twist binding to the promoter of Wnt3 in the indicated
cells with or without TGF-b induction and compared to Mock cells
(immunoprecipitated with IgG). b The cells were treated with shRNA
Twist or negative sequence for 48 h. RT-qPCR was conducted with
Twist primer and the bars in left indicated relative expression of
Twist (mean ± SD from three determinations) adjusted with 18S,
*p\ 0.05 compared to untreated cells. In the right, Western blot was
performed with antibodies specific for Twist and Wnt3. The b-actin
was used for loading control. c The cells were treated with Twist
shRNA or negative control sequence and then induced with or
without TGF-b. The nuclear or cytoplasm expressions of b-catenin
were determined by Western blot analysis. The a-Tubulin and H3
were used for loading control of cytoplasm and nuclear protein
respectively. d The bar graph indicates the regulation of Wnt/b-
catenin pathway signaling in SKBR3 wild type (blue bars), wild-type
cells treated with TGF-b (red bars) and shRNA Twist knocking down
cells (black and green bars) treated with TGF-b compared to
untreated SKBR3 (blue bars) analyzed by specific Wnt/b-catenin
mRNA array. The relative level of each indicated gene was adjusted
with GAPDH and each bar indicates mean fold change and SD from
four determinations
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b led to the upregulation of Twist protein in HER2-over-
expressing epithelial cells.
The A83-01 was reported to be able to block ALK4/5/7
kinase, such that it inhibits not only TGF-b but also activin/
nodal signaling [23]. It has been shown that A83-01 inhi-
bits the transcriptional activity induced by constitutively
active ALK5 and has twice the potency compared to other
small molecular inhibitor for ALK5 [23]. Therefore A83-
01 might be useful for treating cancer progression by
blocking TGF-b-induced EMT. We show in this study that
targeting TGFbRI ALK5 kinase by A83-01 inhibited TGF-
b-induced phosphorylation of Smad3, and subsequently
repressed Twist and prevented TGF-b-induced induction of
Wnt3 and EMT in HER2 cells.
Twist has been shown to transcriptionally repress
E-cadherin gene expression through E-box elements on its
Fig. 5 Targeting TGF-bRI ALK5 kinase by A83-01 inhibited TGF-
b-induced Twist and Wnt3. The cells were incubated with A83-01 for
16 h and then treated with TGF-b at indicated time. A total protein
levels of pSmad3 and Twist were determined by Western blot
analysis. B Localization of pSmad3 (a, c, e Texas red) and Twist (g, i,
k FITC green) protein was determined by Immunofluorescence
analysis (IF) as described in the ‘‘Methods’’ section. White arrows
indicate cytoplasmic expression and yellow arrows indicate nuclear
expression. b, d, f Merged pSmad3-Texas red and cell nuclei labeled
with DAPI blue, and h, j, l merged Twist-FITC (green) and cell nuclei
labeled with propidium iodide (PI) (red). C Localization of b-catenin
was determined by IF. a–c show cell nuclei labeled with PI (red), and
d–f, show b-catenin labeled with FITC (green). g–iMerged b-catenin-
FITC and cell nuclei labeled with PI. White arrows indicate
cytoplasmic expression and yellow arrows indicate nuclear expres-
sion. D Total protein level of Wnt3 was determined by Western blot
analysis
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promoter and by inducing EMT [34]. In this study we
demonstrated for the first time that Twist could regulate
Wnt3 by directly binding to Wnt3 promoter region through
E-box element on its promoter. Therefore, Twist served as
a linkage between TGF-b and canonical Wnt pathways
during the time TGF-b-inducing EMT.
It was known that Twist is not only critical for EMT
process but also necessary for the metastatic process
[35–40]. Through an in vivo mouse model in our previous
study, we found that Twist expression was associated with
mammary tumors that were more likely to exhibit invasive
and metastatic characteristics [41]. Our data in the current
study showed that the angiogenesis- and metastases-asso-
ciated molecules, such as VEGF and MMPs were signifi-
cantly upregulated upon TGF-b induction. As a result, the
cells were more invasive.
It has been reported recently that EMT may not be
required for metastases, but more likely to contribute to
resistance to chemotherapy [42, 43]. We showed in this
study that inhibition of TGF-b-induced EMT by A83-01 in
Fig. 6 A83-01 enhanced inhibition activity of trastuzumab on TGF-
b-induced cell invasion and migration. a SKBR3 cells were treated
with TGF-b, TGF-b plus A83-01, or without any treatment for 4 days
and MTT assay was performed at each day as described in ‘‘Methods’’
section. Each data point was six measurements and the graph showed
mean of six measurements plus standard deviation, *p\ 0.05 and
**p\ 0.01 compared to untreated cells, ^p\ 0.05 and ^^p\ 0.01
compared to the TGF-b treatment alone. b SKBR3 cells were
incubated with A83-01 for 16 h and then the cells were treated with
either TGF-b, trastuzumab, or A83-01 alone or as indicated combi-
nation treatment for 24 h. Cell invasiveness was measured by Boyden
Chamber Invasion assay as described in ‘‘Methods’’ section. The bars
indicated mean number of invaded cells plus stander deviation
counted from five different areas, *p\ 0.05 compared to untreated
cells. c Cell migration was determined by wound healing (Gap
Closure) assay. The cells were pre-treated with or without A83-01 for
16 h and then treated with TGF-b ± Trastuzumab. The photos of cell
migration were taken after 48 h treatment (top). The bar graph in
bottom is quantification of the wound width. The bar indicates the
percentage migration rate (wound width compared to untreated
control cells) of each condition, and three views were counted,
*p\ 0.05 compared to the control cells. d Proposed model of the
feedback loop between TGF-b and Wnt/b-catenin pathways. TGF-b
initiates phosphorylation of Smad3 and nuclear translocation of
pSmad3, and then induces Twist binding to E-box at the Wnt3
promoter to regulate Wnt3 during EMT. The upregulated Wnt3 by
TGF-b in turn activates Wnt/b-catenin signaling to further upregu-
lated EGFR [18] and Smad pathway. The interaction between the two
pathways sustains each other, induces EMT and promotes HER2 cell
resistance to therapy. Targeting TGF-bR1 ALK5 kinase could inhibit
the TGF-b-initiated pathway interactions and enhance HER2 cell
response to trastuzumab treatment
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HER2-overexpressing breast cancer cells enhanced anti-
tumor activity of trastuzumab. Co-targeting TGF-b/Smad
and HER2 pathways has significantly inhibited cell
migration in both SKBR3 and JIMT1 cells.
Therefore, we propose a model in which TGF-b initiated
direct interaction between phosphorylation of Smad3 and
Twist to regulate Wnt3, consequently, induced canonical
Wnt signaling and led to resistance (Fig. 6d). Inhibition of
TGF-b/Smad pathway by A83-01 could prevent the TGF-
b-initiated pathway interaction and inhibit EMT induced
by TGF-b, and subsequently enhance HER2 cell response
to trastuzumab treatment. Our study also suggests that
targeting Twist could inhibit the interaction between TGF-
b and Wnt pathways that could not only prevent breast
cancer progressing to EMT and enhancing sensitivity of
cancer treatment, but could also inhibit the TGF-b- and
Wnt3-induced MMPs and VEGF. Thus, therapeutic tar-
geting of Twist could prevent tumor metastases and
improve outcomes of breast cancer.
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